PGIMER Offers Research Opportunities
6 May 2026

PGIMER Offers Research Opportunities | Salary Rs. 80400 per month

1st class Post Graduate Degree, Including the integrated PG Degree with 3years experience Or 2nd Class Post Graduate Degree, Including the integrated PG Degree with PhD and 03 year experience
6 May 2026
ILBS looking for Life Sciences, Microbiology, Biotechnology, Biochemistry Graduates
Graduate in Science, Life Sciences, Microbiology, Biotechnology, Biochemistry, Public Health, Zoology, Nursing, Social Work, Hospital Management or any other relevant discipline from a recognized institution with 1 year of experience. 
6 May 2026
DBT funded project positions for Life sciences candidates at RCB
PhD or equivalent degree in Life Sciences with at least one research paper in Science Citation Indexed journal.
6 May 2026
Dr. Reddy’s Lab Career-Expo for Pharma and Science candidates
Sterile equipment qualification experience with SAT, IQ, OQ, PQexecution, including autoclave, tunnel, filling/capping machines, Lyo, washing and related systems.
6 May 2026
Production, Warehouse and Packaging & Development Openings at Natco Pharma
B.Pharm with P.G Diploma in Packaging from IIP ; Diploma / B. Pharmacy / M. Pharmacy
6 May 2026
Opportunities in Quality Function for Sciences / Pharmacy candidates at Pfizer
Serve on cross-functional teams, conduct safety inspections, participate in investigations, recommend corrective actions, and train junior colleagues.
6 May 2026
Walk In Drive for Production, QC, QA Department at CORONA Remedies
Analysis of Raw Material, In-process, Finish Products, Stability Tastings. Process Validation, participate in Lab incident/OOS/OOT/Analytical deviation.
6 May 2026
QC, QA, Production Jobs at Gracure Pharmaceutical | B.Pharma / M.Pharma / MSc job role
B.Pharma/ M.Pharma/ Msc; Relevant functional experience in regulatory approved facilities at Gracure Pharmaceutical
6 May 2026
Gufic Biosciences Hiring Pharma, Chemistry, Microbiology, Biotechnology professionals
M.Pharm / B.Pharm / D.Pharm / M.Sc (Chemistry/Organic Chemistry / Microbiology, Biotechnology) 
6 May 2026
Lilly’s Omvoh Shows 4-Year Durable Disease Clearance in Ulcerative Colitis

New long-term data from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) treated with Omvoh (mirikizumab-mrkz) achieved durable disease clearance through four years of continuous treatment. In the LUCENT-3 open-label extension study, 63.5% of Omvoh-treated patients who achieved disease clearance at one year sustained it at four years.